DOCSLIB.ORG

Prostate Cancer: a Comprehensive Perspective Ash Tewari, MD Ronald P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prostate Cancer: a Comprehensive Perspective Ash Tewari, MD Ronald P Prostate Cancer: A Comprehensive Perspective Ash Tewari, MD Ronald P. Lynch Professor of Urologic-Oncology Director Weill Cornell Medical College and New York Presbyterian Hospital Center for Prostate Cancer Research and Clinical Care (CPCR&CC) Director Lefrak Center of Robotic Surgery, NYPH Ashutosh Tewari Editor Prostate Cancer: A Comprehensive Perspective Editor Ashutosh Tewari New York Presbyterian Hospital Brady Urologic Health Center Weill Cornell Medical Center New York New York USA ISBN 978-1-4471-2863-2 ISBN 978-1-4471-2864-9 (eBook) DOI 10.1007/978-1-4471-2864-9 Springer London Heidelberg New York Dordrecht Library of Congress Control Number: 2013931841 © Springer-Verlag London 2013 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, speci fi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on micro fi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied speci fi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher’s location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a speci fi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Foreword Prostate cancer has become a worldwide problem, not only in the developed world but in developing countries as well. As the population ages worldwide and other diseases become less frequent causes of premature death, prostate cancer, which rapidly increases in frequency with age, will present a growing public health problem. Prostate cancer is a complex and het- erogeneous disease. The ratio of deaths to new cases is one of the lowest of any of the major internal organ solid tumors. It is well known that most men die with, rather than of, prostate cancer, a paradox that has long stymied widespread understanding and the easy development of consensus about the management of this disease. Fortunately, clinical and basic research in the past 20 years have provided important tools that have enormously facilitated our understanding of prostate cancer, the ability to predict the course of the disease and the outcomes of various treatments. Today we can add to the standard clinical factors (stage, grade, PSA and biopsy results) the burgeoning technology of medical imaging (especially magnetic resonance imaging) and the more recent molecular characteriza- tions that could greatly enhance our ability to identify the threat posed by the cancer in any given patient. Further characterization of prostate cancer seems highly likely over the next decade with the expanding use of genomic analysis. The worldwide effort to characterize the prostate cancer genome will prove enormously fruitful and markedly increase our ability to discriminate between potentially lethal and indolent prostate cancers. The biomarker prostate speci fi c antigen (PSA) has revolutionized our understanding and ability to manage this disease. While PSA testing has proved the source of enormous debate over the last decade, it is clear that PSA is the best biomarker available in oncology. Recent studies have shown that a man’s PSA levels in his 40s, 50s, and 60s strongly predict the likeli- hood that he will ever develop advanced prostate cancer or die of the disease. Nevertheless, controversy swirls around the optimum protocol for PSA testing, the age of onset of testing, and the cost bene fi t of screening for prostate cancer. Epidemiological data show that in coun- tries where screening has been widely used, mortality from prostate cancer has been declining steadily and rapidly. Today, in the United States, the age-speci fi c mortality rate from prostate cancer has fallen by nearly 50 % over the last 15 years. The treatment of prostate cancer is also undergoing revolutionary changes. Technology has expanded the surgical options for radical prostatectomy, which now include robotic and free- hand laparoscopic as well as open retropubic and perineal techniques. Radiation therapy has also bene fi ted from a technological advance. Intensity-modulated radiation has allowed us to safely deliver doses as high as 86 Gy to the prostate, and image guidance promises to target the prostate more accurately, improving cancer control. Many centers have developed combina- tions of interstitial radiation (brachytherapy) with external beam radiation to deliver higher doses. Proponents of proton beam therapy argue that it offers an even greater therapeutic index, although there is little clinical data to support the contention. For those with metastatic prostate cancer, this is indeed an exciting era. There are over 100 new drugs in the pipeline for commercial development in the United States alone. Phase III clinical trials have shown substantially increased survival with new drugs that target the andro- gen receptor, such as abiraterone and Medivation 3100. The fi rst immunotherapy approved for use in human cancer was sipuleucel-T, approved for prostate cancer. Other exciting approaches v vi Foreword include immunomodulation with anti-CTLA4 antibodies and with monoclonal antibodies tar- geting B7x and other immunoinhibitory targets. These and many other exciting developments in prostate cancer are addressed in detail in this remarkable new book edited by Ashutosh Tewari and an international team of associate editors. Every possible aspect of prostate cancer is covered by a recognized authority in the fi eld. For those deeply interested in understanding this disease, especially clinical and labora- tory investigators, and for physicians and surgeons who devote their careers to treating men with prostate cancer, this book is a major new addition to the fi eld. Peter T. Scardino Contributors Associate Editors Anthony J. Costello, M.D., FRACS Professor, Royal Melbourne Hospital, Department of Urology, 32 Erin Street, Richmond, Victoria 3121, Australia; 61-3-9429-9555; [email protected] vii viii Contributors Mahesh Desai, M.S., FRCS (Eng), FRCS (Edin) Medical Director, Muljibhai Patel Urological Hospital, Department of Urology, Dr. V.V. Desai Road, Nadiad, Gujarat 387 001, India; +91 268 2520323; fax +91 268 2520248; [email protected] James A. Eastham, M.D. Chief, Urology Service, Memorial Sloan-Kettering Cancer Center, Department of Surgery, 1275 York Avenue, New York, NY 10065, USA; 646-422-4390; fax 212-988-0806; [email protected] Contributors ix John M. Fitzpatrick, MCh, FRCSI, FC Urol (SA), FRCSGlas, FRCS Head of Research, Irish Cancer Society, 43/45 Northumberland Road, Dublin 4, Ireland; Professor of Surgery, Consultant Urologist, Mater Misericordiac Hospital, University College, Dublin, Ireland; +353 1 231 0564; fax +353 1 231 0555; j fi [email protected] Martin Gleave, M.D., FRCSC, FACS British Columbia Leadership Chair; Distinguished University Scholar; Professor, Department of Urological Sciences, UBC; Director, The Vancouver Prostate Centre; Vancouver General Hospital, Vancouver Prostate Centre, DHCC, 6th Floor, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9, Canada; 604-875-5006; fax 604-875-5024; [email protected] x Contributors David Neal, FMedSci, M.S., FRCS Professor of Surgical Oncology, University of Cambridge/Addenbrooke’s Hospital, Department of Oncology/Department of Urology, Box 279(S4), Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, UK; 01223 331940; fax 01223 769007; [email protected] Contributors xi Francisco J. B. Sampaio, M.D., Ph.D. Full Professor and Chairman, Urogenital Research Unit, State University of Rio de Janeiro; University Hospital, State University of Rio de Janeiro, Department of Surgery, Rua Siqueira Campos, 30-1101, Copacabana, Rio de Janeiro 22031-070, Brazil; +55 21 9974-8168; +55 21 2548-0636; [email protected] xii Contributors Prasanna Sooriakumaran, BMedSci (Hons), BMBS (Hons), MRCS, Ph.D., PGCMedLaw, FRCS (Urol), ADC (ClinInv) New York Presbyterian Hospital/Weill Cornell Medical College, James Buchanan Brady Foundation Department of Urology, 525 East 68th Street, New York, NY 10065, USA; [email protected] Contributors xiii E. Darracott Vaughan, Jr., M.D. Professor Emeritus, Weill Cornell Medical College, New York Presbyterian Hospital, Department of Urology, 525 East 68th Street, New York, NY 10065, USA; [email protected]
Load more

Recommended publications
  • British Journal of Urology International July 2005 - Vol
    British Journal of Urology International July 2005 - Vol. 96 Issue 1 Page i-205 i Editor's comment Online publication date: 17-Jun-2005 Comments 1 Beyond marketing: the real value of robotic radical prostatectomy Anthony J. Costello Online publication date: 17-Jun-2005 2 Prolonging survival in prostate cancer: chemotherapy will have an important role Chris Parker, Mark Emberton Online publication date: 17-Jun-2005 3 -acylmethyl co-enzyme A racemase: a tumour marker for the 21st century? Debashis Das, Prokar Dasgupta, Asish Chandra Online publication date: 17-Jun-2005 4 The 'flare' phenomenon: should we be concerned? Ramesh Thurairaja, Rajendra Persad, John Peters, Amit Bahl Online publication date: 17-Jun-2005 Mini-reviews 7 Molecular staging of bladder cancer Anirban P. Mitra, Ram H. Datar, Richard J. Cote Online publication date: 17-Jun-2005 13 The role of hand-assisted laparoscopy in urology: a critical appraisal Abhay Rane, J. Stuart Wolf Online publication date: 17-Jun-2005 17 The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer Sunjay Jain, Roger C. Kockelbergh Online publication date: 17-Jun-2005 22 Nonsurgical factors in the success of hypospadias repair Christopher R.J. Woodhouse, Deborah Christie Online publication date: 17-Jun-2005 Urological Oncology 29 Racial differences in serum prostate-specific antigen (PSA) doubling time, histopathological variables and long-term PSA recurrence between African-American and white American men undergoing radical prostatectomy for clinically localized prostate cancer Ashutosh Tewari, Wolfgang Horninger, Ketan K. Badani, Mazen Hasan, Steven Coon, E. David Crawford, Eduard J. Gamito, John Wei, David Taub, James Montie, Chris Porter, George W.
    [Show full text]
  • Pagina 1 Di 304 SBBL - SPRINGER E-BOOKS : TITOLI CORRENTI 2014 N
    SBBL - SPRINGER E-BOOKS : TITOLI CORRENTI 2014 N. Book Title Author Year Editore n. 1 (Endo)symbiotic Methanogenic Archaea Johannes H.P. Hackstein 2010 Springer Berlin Heidelberg n. 2 20 Years of Computational Neuroscience Tim R. New 2011 Springer Netherlands n. 3 25 Years of p53 Research James M Bower 2013 Springer New York n. 4 34th Hemophilia Symposium Pierre Hainaut, Klas G. Wiman 2005 Springer Netherlands n. 5 35th Hemophilia Symposium I. Scharrer, W. Schramm 2005 Springer Berlin Heidelberg n. 6 36th Hemophilia Symposium Hamburg 2005 Inge Scharrer, Wolfgang Schramm 2006 Springer Berlin Heidelberg n. 7 37th Hemophilia Symposium Inge Scharrer, Wolfgang Schramm 2007 Springer Berlin Heidelberg n. 8 3D Histology Evaluation of Dermatologic Surgery Inge Scharrer, Wolfgang Schramm 2008 Springer Berlin Heidelberg n. 9 41es Journées nationales de la Société Française de Médecine Périnatale (Grenoble 12–14 octobre 2011) Helmut Breuninger, Patrick Adam 2013 Springer London n. 10 42es Journées nationales de la Société Française de Médecine Périnatale (Montpellier 17–19 octobre 2012) Société Française de Médecine Périnatale 2011 Springer Paris n. 11 50 Years of Phytochemistry Research Société Française de Médecine Périnatale 2013 Springer Paris n. 12 55 Years German Society of Anaesthesiology and Intensive Care Medicine David R. Gang 2013 Springer International Publishing n. 13 5-HT2C Receptors in the Pathophysiology of CNS Disease J. Schüttler 2012 Springer Berlin Heidelberg n. 14 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center Giuseppe Di Giovanni, Ennio Esposito, Vincenzo Di Matteo 2011 Humana Press n. 15 7.0 Tesla MRI Brain Atlas M.
    [Show full text]
  • Final1-223234-1128453-Finalreport-03.Pdf
    O PROJECT FINAL REPORT Grant Agreement number: 223234 Project acronym: INCOMB Project title: Combating Incontinence, from basic science to clinical practice Funding Scheme: FP7-CP-FP Period covered: from 2008-12-01 to 2012-05-31 1 Name of the scientific representative of the project's co-ordinatorPF F,P Prof. Anders Arner Department of Physiology and Pharmacology Karolinska Institutet SE 171 77 Stockholm Sweden Tel: +46 8 524 87221 E-mail: [email protected] Project website address: www.INComb.eu 1 TP PT Usually the contact person of the coordinator as specified in Art. 8.1. of the Grant Agreement. 4.1 Final publishable summary report 4.1.1 Executive summary Urinary incontinence and the problems of urgency and frequency of micturition are conditions affecting a large number of European citizens. An “over active bladder” (OAB) due to involuntary bladder muscle contractions is the major cause of urgency incontinence. Although this and other lower urinary tract symptoms do not constitute life threatening disorders, they do have serious negative impact on the quality of life and major effects on health economy. Several therapies are used to treat urgency incontinence. However, currently, these treatments are imperfect or are associated with adverse side effects which reduce patient compliance. The INComb project, “Combating incontinence” (www.INComb.eu), was initiated, with the aims of establishing a better understanding of the pathogenesis of bladder overactivity, improving diagnostic tests and developing novel intervention strategies. The urinary bladder is a complex organ where different cell types and tissues influence the filling and emptying of urine. The project has addressed objectives related to the communication between the different cell types and has developed novel techniques to measure signalling components in urinary bladder tissue.
    [Show full text]
  • Book Title Author Copyright Year Editore N.1 (Endo)Symbiotic Methanogenic Archaea Johannes H.P
    SBBL - SPRINGER E-BOOKS : TITOLI CORRENTI 2013 Book Title Author Copyright Year Editore n.1 (Endo)symbiotic Methanogenic Archaea Johannes H.P. Hackstein 2010 Springer n.2 ‘In Considerable Variety’: Introducing the Diversity of Australia’s Insects Tim R. New 2011 Springer n.3 25 Years of p53 Research Pierre Hainaut, Klas G. Wiman 2005 Springer n.4 34th Hemophilia Symposium I. Scharrer, W. Schramm 2005 Springer n.5 35th Hemophilia Symposium Inge Scharrer, Wolfgang Schramm 2006 Springer n.6 36th Hemophilia Symposium Hamburg 2005 Inge Scharrer, Wolfgang Schramm 2007 Springer n.7 37th Hemophilia Symposium Inge Scharrer, Wolfgang Schramm 2008 Springer n.8 41es Journées nationales de la Société Française de Médecine Périnatale (Grenoble 12–14 octobre 2011) Société Française de Médecine Périnatale 2011 Springer n.9 42es Journées nationales de la Société Française de Médecine Périnatale (Montpellier 17–19 octobre 2012) Société Française de Médecine Périnatale 2013 Springer n.10 55 Years German Society of Anaesthesiology and Intensive Care Medicine J. Schüttler 2012 Springer n.11 5-HT2C Receptors in the Pathophysiology of CNS Disease Giuseppe Di Giovanni, Ennio Esposito, Vincenzo Di Matteo 2011 Springer n.12 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center M. Alma Rodriguez, Ronald S. Walters, Thomas W. Burke 2013 Springer n.13 7.0 Tesla MRI Brain Atlas Zang-Hee Cho 2010 Springer n.14 99mTc-Sestamibi Jan Bucerius, Hojjat Ahmadzadehfar, Hans-Jürgen Biersack 2012 Springer n.15 A Blueprint for Promoting Academic and Social Competence in After-School Programs Thomas P. Gullotta, Martin Bloom, Christianne F.
    [Show full text]
  • Helping Patients Counter Obesity by Achieving Enduring Lifestyle Change
    Place comment_Layout 1 16/11/2011 09:36 Page 1 COMMENT 39 Getting to a better ‘PLACE’: helping patients counter obesity by achieving enduring lifestyle change ROGER KIRBY, MICHAEL KIRBY, PETER AMOROSO, BEN CHALLACOMBE, PROKAR DASGUPTA, CULLEY CARSON III AND JOHN M. FITZPATRICK In the domain of public health, common sense is not always common practice. How best then to enable patients to act on the advice that they have constantly heard, but find hard to actually carry out? besity, especially male-pattern modifications that can help to Oabdominal obesity, is strongly achieve, and maintain, significant correlated with hypertension, diabetes, weight reduction. dyslipidaemia and consequent cardiovascular risk.1 It is also linked with We advise our patients to ‘get to erectile dysfunction (ED) and increased risk a better PLACE’ and achieve the of benign prostatic hyperplasia (BPH), as balance between energy intake well as greater morbidity after treatment and calorie use that provides for prostate cancer.2 Although diets the key to weight reduction. low in carbohydrates and energy-rich A mnemonic of five simple rules fats are often successful in achieving acts as an aide mémoire for both clinician weight reduction, their impact is often and patient (Figure 1): Figure 1. Getting to a better PLACE disappointingly short-lived, so that their (patient handout available from long-term efficacy is limited. A urologist is ortion control. Generally speaking, the www.trendsinurology.com/patientinformation) frequently the first clinician that a patient, Pportions of energy-rich foods, eaten especially a middle-aged male patient, both at and away from home, are much comes into contact with.
    [Show full text]
  • Huntprg2 1..4
    HUNTERIAN SOCIETY Programme of 187th Session 2012±2013 President: Professor Prokar Dasgupta Programme of 187th Session 2012 Monday 24th September ± Inaugural Meeting 6.30±8.30pm The Hunterian Museum: Professor Harold Ellis CBE, FRCS Cutting of the Stone ± History of the Bladder Stone Royal College of Surgeons of England Lincolns Inn Fields WC2A 3PE Presentation of the Hunterian Scholarships Thursday 4th October ± 4.45pm Westminster Abbey Commemoration of the Anniversary of the Death of John Hunter on October 16th 1793 Evensong followed by a supper at The Cinnamon Club 30±32 Great Smith Street SW1P 3BU Monday 29th October ± Scientific Dinner Meeting Council Meeting 6.00pm Medical Society of London 11 Chandos Street W1G 9EB Dr Nicholas Cambridge, MD, MRCS From the Slaughter House of Blood to Mr Pickwick: Charles Dickens and Medicine Monday 19th November ± Presidential Address Medical Society of London 11 Chandos Street W1G 9EB Professor Prokar Dasgupta, MSc, DLS, MD, FRCS, FRCS(Urol), FEBU Botulinum Toxin ± from Deadly Poison to Urology * Timetable for meetings unless otherwise stated 7.00pm Reception and Dinner 8.15pm Scientific Meeting { 9.30pm End { Fellows may attend the Scientific Meeting only. Programme of 187th Session 2013 Monday 21st January ± Hunterian Prize Papers & Award Council Meeting 6.00pm Medical Society of London 11 Chandos Street W1G 9EB Tuesday 5th February ± Guest Lecture and Anniversary Dinner The Athenaeum 107 Pall Mall SW1 5ER Professor Clare Fowler, CBE, MSc, FRCP The Bladder and its Nerve Supply Monday 18th March ± Hunterian Oration Medical Society of London 11 Chandos Street W1G 9EB Professor Roger Kirby, MA, MD, FRCS, FEBU The Prostate ± Hunter and Beyond Monday 15th April ± Hunterian Lecture Council Meeting 6.00pm Medical Society of London 11 Chandos Street W1G 9EB Mr Andy Leather, MS, FRCS Applying Hunterian Principles to the Challenges of Global Health Monday 20th May ± Annual General Meeting and Scientific Dinner Meeting Medical Society of London 11 Chandos Street W1G 9EB Dr Stuart McDonald BSc, MB.ChB., PhD.
    [Show full text]
  • M Eeting Program
    2019 MAY 3–6 chicago MEETING PROGRAM METS? NO METS? START XTANDI. Regardless of metastatic status, XTANDI offers your patients with castration-resistant prostate cancer (CRPC) the confi dence of proven effi cacy when PSA is rising* during LHRH therapy.†1 *PSA level ≥ 2 ng/mL with at least 2 consecutive rises despite castrate testosterone levels (≤ 50 ng/dL).2-4 Indication and Important Safety Information Indication Advise patients who experience any symptoms of hypersensitivity to temporarily discontinue XTANDI and promptly seek medical care. XTANDI (enzalutamide) is indicated for the treatment of patients with Permanently discontinue XTANDI for serious hypersensitivity reactions. castration-resistant prostate cancer (CRPC). Ischemic Heart Disease In the placebo-controlled clinical studies, Important Safety Information ischemic heart disease occurred more commonly in patients on the XTANDI arm compared to patients on the placebo arm (2.7% vs 1.2%). Warnings and Precautions Grade 3-4 ischemic events occurred in 1.2% of patients on XTANDI versus Seizure occurred in 0.4% of patients receiving XTANDI in clinical studies. 0.5% on placebo. Ischemic events led to death in 0.4% of patients on In a study of patients with predisposing factors for seizure, 2.2% of XTANDI compared to 0.1% on placebo. Monitor for signs and symptoms XTANDI-treated patients experienced a seizure. Patients in the study had of ischemic heart disease. Optimize management of cardiovascular risk one or more of the following pre-disposing factors: use of medications factors, such as hypertension, diabetes, or dyslipidemia. Discontinue that may lower the seizure threshold; history of traumatic brain or head XTANDI for Grade 3-4 ischemic heart disease.
    [Show full text]
  • British Journal of Urology International( April 2005 )
    British Journal of Urology International April 2005 - Vol. 95 Issue 6 Page i-927 i Editor's comment Online publication date: 24-Mar-2005 Comments 723 Robotic urology in the UK: establishing a programme and emerg Prokar Dasgupta, Ashok Hemal, Kirsten Rose, the Guy's and St. Online publication date: 24-Mar-2005 724 Laparoscopic reconstructive urology Sravanti P. Tegavarupu, Prokar Dasgupta Online publication date: 24-Mar-2005 726 Drug-eluting biomaterials in urology: the time is ripe Bodo E. Knudsen, Ben H. Chew, John D. Denstedt Online publication date: 24-Mar-2005 727 The European working-time directive: one step forward, two ste Majid Shabbir, Peter Amoroso, Roger S. Kirby Online publication date: 24-Mar-2005 Mini-reviews 729 Peyronie's disease: the epidemiology, aetiology and clinical eval Christopher J. Smith, Chelsea McMahon, Ridwan Shabsigh Online publication date: 24-Mar-2005 733 Recent advances in understanding the biology of diabetes-associ and novel therapy Naoki Yoshimura, Michael B. Chancellor, Karl-Erik Andersson Online publication date: 24-Mar-2005 739 Molecular prognostic factors in bladder cancer Maurizio Buscarini, Marcus L. Quek, Parkash Gill, Guangbin Xia, David I. Quinn, John P. Stein Online publication date: 24-Mar-2005 743 An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases Christopher P. Evans, Neil Fleshner, John M. Fitzpatrick, Alexander R. Zlotta Online publication date: 24-Mar-2005 Urological Oncology 751 Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome John F. Ward, Jeffrey M. Slezak, Michael L.
    [Show full text]